DENGUE VACCINES IN ENDEMIC SETTINGS: A LONG-AWAITED GAME CHANGER?
Keywords:
Dengue vaccine, Severe dengueAbstract
I read with great interest the article by Ramzan et al.¹ titled “Dengue Epidemics: Knowledge Perhaps is the Only Key to Success.” While public awareness and vector control remain essential strategies, the recent advancements in dengue vaccine development may represent a long-awaited turning point in the fight against this global health threat, particularly in endemic settings.
References
1. Ramzan M, Ansar A, Nadeem S. Dengue epidemics: knowledge perhaps is the only key to success. J Ayub Med Coll Abbottabad 2015;27(2):402–6.
2. Chang CY, Rajappan M, Zaid M, Ong ELC. Dengue fever complicated by hemophagocytic lymphohistiocytosis: Report of 2 cases and bone marrow findings. Clin Case Rep 2020;8(12):3427–3431.
3. Mashudi DN, Ahmad N, Mohd Said S. Level of dengue preventive practices and associated factors in a Malaysian residential area during the COVID-19 pandemic: A cross-sectional study. PLoS One 2022;17(4):e0267899.
4. World Health Organization. Dengue and severe dengue [Internet]. Geneva: WHO; 2023 [cited 2025 Aug]. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
5. Chem YK, Yenamandra SP, Chong CK, Mudin RN, Wan MK, Tajudin N, et al. Molecular epidemiology of dengue in Malaysia: 2015–2021. Front Genet 2024;15:1368843.
6. Bäck AT, Lundkvist A. Dengue viruses – an overview. Infect Ecol Epidemiol 2013;3:19839.
7. Malavige GN, Ogg GS. Pathogenesis of vascular leak in dengue virus infection. Immunology 2017;151(3):261–69.
8. Tejo AM, Hamasaki DT, Menezes LM, Ho YL. Severe dengue in the intensive care unit. J Intensive Med 2023;4(1):16–33.
9. Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S, et al. Risk predictors of progression to severe disease during the febrile phase of dengue: A systematic review and meta-analysis. Lancet Infect Dis 2021;21(7):1014–26.
10. Kok SY, Abraham RE, Jauhar Ali SN, Tuang WX, Ong ELC. A retrospective study of clinical biomarkers of severe dengue in a tertiary hospital in Johor Bahru, Malaysia. Trop Med Infect Dis 2025;10(2):30.
11. Thomas SJ. Is new dengue vaccine efficacy data a relief or cause for concern? NPJ Vaccines 2023;8(1):55.
12. Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O’Brien K, Vannice K, et al. Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis 2019;19(1):e31–e38.
13. Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C, et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health 2024;12(2):e257–70.
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Chee Yik Chang, Edmund Liang Chai Ong
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
